Global Cardiopulmonary Bypass Equipment Market, by Product Type (Single Roller Pump and Double Roller Pump), by End User (Hospitals and Ambulatory Surgical Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 118.0 Million in 2022 and is expected to exhibit a CAGR of 1.7% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing research and development activities for the cardiopulmonary bypass equipment is expected to drive growth of the market over the forecast period. For instance, in May 2022, Xoran Technologies, LLC. , the innovator and market leader in compact, specialized medical CT scanners had completed phase 1 for their NHLBI grant for mobile lung CT. Xoran Technologies was notified of a grant award from the National Heart, Lung, and Blood Institute (NHLBI) to support the company's research and development efforts for lung cone beam computed tomography (CBCT) imaging. Leveraging its knowledge and experience in the field as pioneer and medical market leader in CBCT, Xoran has proposed an open-bore, truly mobile CT to assist in identification of lung disease.
Global Cardiopulmonary Bypass Equipment Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
However, the COVID-19 pandemic had a negative impact on the global cardiopulmonary bypass equipment market, owing to decrease in the demand for the cardiopulmonary bypass equipment. For instance, in September 2020, according to National Center for Biotechnology Information, in response to the burden of COVID‐19 on healthcare systems in the U.K., elective cardiac surgeries had been delayed owing to the redistribution of intensive care resources and the unquantifiable risk of acquiring COVID‐19. Current evidence is limited for postoperative outcomes in cardiac surgery cases. The decrease is the number of surgeries performed for heart and lung limited the production of cardiopulmonary bypass equipment. In the COVID-19 pandemic the lockdown restriction for avoiding the risk of spreading the coronavirus infection resulted in the delay of cardiac surgery.
Global Cardiopulmonary Bypass Equipment Market: Key Developments
In April 2022, LivaNova, PLC, a company that develops devices used for cardiac surgery and neuromodulator, announced receipt of regulatory approvals and the start of a targeted commercial launch for the Essenz Patient Monitor. The transformative monitoring system uses a patient-tailored approach to improve clinical efficiency and quality of patient care during cardiopulmonary bypass (CPB) procedures. LivaNova, PLC, had recently received U.S. Food and Drug Administration 510(k) clearance and CE Mark, LivaNova initially launched the Essenz Patient Monitor in the U.S. and Europe in hospitals that were involved in its user-centric design and development program. Additionally, the patient monitor provides important decision-making support for the perfusionist during the entire CPB procedure, is compatible with the LivaNova S heart-lung machine and will be a key feature of the complete Essenz Perfusion System, which encompasses a next-generation heart-lung machine. The Essenz Perfusion System is currently under development and is expected to launch in stages with limited commercial launches.
Browse 22 Market Data Tables and 19 Figures spread through 157 Pages and in-depth TOC on “Global Cardiopulmonary Bypass Equipment Market”- Forecast to 2030, Global Cardiopulmonary Bypass Equipment Market, by Product Type (Single Roller Pump and Double Roller Pump), by End User (Hospitals and Ambulatory Surgical Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights related to Global Cardiopulmonary Bypass Equipment Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/cardiopulmonary-bypass-equipment-market-2026
Key Takeaways of the Global Cardiopulmonary Bypass Equipment Market:
- The global cardiopulmonary bypass equipment market is expected to exhibit a CAGR of 1.7% during the forecast period due to the increasing adoption of inorganic growth strategies such as acquisition by the key players in the market for developing cardiopulmonary bypass equipment. For instance, in January 2022, Medtronic plc, a company that provides medical technology, services, and solutions acquired Affera, Inc., medical technology company to expand the Medtronic portfolio of advanced cardiac ablation products and accessories to meet physician needs within a growing patient population. Affera's technologies include the Affera Prism-1 cardiac mapping and navigation platform and Sphere-9 cardiac ablation catheter, investigational technologies designed to enable the rapid creation of detailed maps used by electrophysiologists (EP) to diagnose arrhythmias and deliver cardiac ablation therapy, respectively. The Affera full-suite of solutions and technologies will complement the existing Medtronic atrial and ventricular arrhythmia disease management portfolio and support the company's efforts to offer simple, safe, and effective cardiac ablation solutions to improve patient outcomes.
- Asia Pacific is expected to witness fastest growth in the global cardiopulmonary bypass equipment market due to increasing patient pool and growing medical tourism for various surgeries in the region.
- Major players operating in the global cardiopulmonary bypass equipment market include Medtronic Plc, LivaNova PLC, MAQUET Holding B.V. & Co. KG., Terumo Corporation, Braile Biomedica, and Tianjin Medical
